{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T19:56:42Z","timestamp":1778788602544,"version":"3.51.4"},"reference-count":43,"publisher":"BMJ","funder":[{"name":"National Institutes of Health, University of the Philippines Manila"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,6,29]]},"abstract":"<jats:p>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are two related mucocutaneous disorders with different severities. Although the incidence is low, SJS and TEN are life-threatening and predominantly drug-induced conditions. There is a strong relationship between the <jats:italic>HLA-B*1502<\/jats:italic> allele and carbamazepine-induced SJS and TEN in different Southeast Asian populations. Here, we report a case of Filipino with SJS\/TEN overlap probably induced by carbamazepine. The condition was treated with hydrocortisone followed by prednisone. The <jats:italic>HLA-B*1502<\/jats:italic> allele was not found in this case. The patient tested positive for the HLA-B75 serotype, suggesting that carbamazepine-induced SJS\/TEN may be serotype specific. Establishing the genotype before initiation of the drug may be advantageous for some patients and will aid physicians in determining the optimal drug therapy. Prevention of adverse drug reactions (ADR) may be done if pharmacists and other healthcare professionals work as a multidisciplinary ADR team to ensure that safe medication practices are realised.<\/jats:p>","DOI":"10.1136\/bcr-2018-225028","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T09:05:22Z","timestamp":1531818322000},"page":"bcr-2018-225028","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Carbamazepine-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis overlap in a Filipino with positive HLA-B75 serotype"],"prefix":"10.1136","volume":"2018","author":[{"given":"Francis","family":"Capule","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand"},{"name":"Department of Pharmacy, College of Pharmacy, University of the Philippines Manila, Manila, Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramote","family":"Tragulpiankit","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surakameth","family":"Mahasirimongkol","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuanjun","family":"Wichukchinda","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiraphun","family":"Jittikoon","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara Theresa","family":"Alentajan-Aleta","sequence":"additional","affiliation":[{"name":"Section of Allergy and Immunology, Department of Medicine, Philippine General Hospital and College of Medicine, University of the Philippines Manila, Manila, Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay-V","family":"James Barit","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medicine, Philippine General Hospital and College of Medicine, University of the Philippines Manila, Manila, Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Casanova-Gutierrez","sequence":"additional","affiliation":[{"name":"Section of Adult Neurology, Department of Neurosciences, Philippine General Hospital and College of Medicine, University of the Philippines Manila, Manila, Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonor","family":"Cabral-Lim","sequence":"additional","affiliation":[{"name":"Section of Adult Neurology, Department of Neurosciences, Philippine General Hospital and College of Medicine, University of the Philippines Manila, Manila, Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Paciano","family":"Baltazar Reyes","sequence":"additional","affiliation":[{"name":"Section of Adult Neurology, Department of Neurosciences, Philippine General Hospital and College of Medicine, University of the Philippines Manila, Manila, Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Roa","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medicine, Philippine General Hospital and College of Medicine, University of the Philippines Manila, Manila, Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina Faith","family":"San Gabriel","sequence":"additional","affiliation":[{"name":"Section of Allergy and Immunology, Department of Medicine, Philippine General Hospital and College of Medicine, University of the Philippines Manila, Manila, Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine Lynn","family":"Silao","sequence":"additional","affiliation":[{"name":"Institute of Human Genetics, National Institutes of Health, University of the Philippines Manila, Manila, Philippines"},{"name":"Department of Pediatrics, Philippine General Hospital and College of Medicine, University of the Philippines Manila, Manila, Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,7,17]]},"reference":[{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311906"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.2","unstructured":"Farkas R . Clinical review, adverse events of Carbamazepine. 2007 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/016608s098,020712s029,021710_clinrev.pdf (cited 2017 Oct 12)."},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.3","unstructured":"Onishi ECC , Roa FDC . Stevens-Johnson syndrome and toxic epidermal necrolysis at the Philippine General Hospital: A seven-year retrospective study (January 2004 to December 2010). 2013. JPDS."},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.dsi.2013.09.007","article-title":"Epidemiology of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Southeast Asia","volume":"31","author":"Lee","year":"2013","journal-title":"Dermatologica Sinica"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.5","unstructured":"Uppsala Monitoring Centre. Carbamazepine. 2016. updated 1 Aug 2016, cited 12 Oct 2017 https:\/\/vigilyze.who-umc.org\/#\/."},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.6","unstructured":"U.S. Food and Drug Administration. Information for Healthcare Professionals: Dangerous or Even Fatal Skin Reactions - Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). 2007. updated 14 August 2013; cited 5 October 2017 http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124718.htm."},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.7","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.4.442"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2006.00912.x"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701033"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.10","unstructured":"Quetiapine fumarate (Seroquel\u00ae). Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2010."},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.11","doi-asserted-by":"publisher","DOI":"10.1038\/428486a"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.12","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000199500.46842.4a"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01022.x"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01719.x"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.15","first-page":"252","article-title":"Association between HLA-B*1502 allele and cutaneous reactions induced by carbamazepine or lamotrigine in Han Chinese","volume":"50","author":"Liao","year":"2009","journal-title":"Epilepsia"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.16","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.57718"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02533.x"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.yebeh.2010.08.007","article-title":"Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China","volume":"19","author":"Wu","year":"2010","journal-title":"Epilepsy Behav"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04745.x"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1009-4"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2011.02.003"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.22","first-page":"290","article-title":"Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients","volume":"29","author":"Then","year":"2011","journal-title":"Asian Pac J Allergy Immunol"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00479.x"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.24","doi-asserted-by":"crossref","first-page":"n\/a","DOI":"10.1111\/j.1742-7843.2012.00868.x","article-title":"Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502?","volume":"111","author":"Shi","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.25","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.55"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.26","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12802"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.27","first-page":"S16","article-title":"Association between HLA-B*15:02 allele and antiepileptic drug-induced severe cutaneous reactions in Hong Kong Chinese: a population-based study","volume":"20","author":"Kwan","year":"2014","journal-title":"Hong Kong Med J"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5415\/apallergy.2015.5.2.68","article-title":"HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese","volume":"5","author":"Nguyen","year":"2015","journal-title":"Asia Pac Allergy"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2011.08.010"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.30","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.11.1617"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2008.00548.x"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01457.x"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.33","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3282f3ef9c"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02766.x"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.35","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.2217\/pgs-2017-0103","article-title":"Association of the HLA-B alleles with carbamazepine-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype","volume":"18","author":"Yuliwulandari","year":"2017","journal-title":"Pharmacogenomics"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009717"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.37","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31826aac73"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.38","first-page":"27","article-title":"Pharmacogenomics screening of HLA-B*1502 in epilepsy patients: How we do it in the UKM Medical Centre, Malaysia","volume":"18","author":"Then","year":"2013","journal-title":"Neurology Asia"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.39","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11096-013-9777-9","article-title":"Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand","volume":"35","author":"Tiamkao","year":"2013","journal-title":"Int J Clin Pharm"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.40","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12325"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.41","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2217\/pgs-2015-0009","article-title":"A success story in pharmacogenomics: genetic ID card for SJS\/TEN","volume":"17","author":"Sukasem","year":"2016","journal-title":"Pharmacogenomics"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.42","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-014-0023-x"},{"key":"2025082723175609000_2018.jul17_1.bcr-2018-225028.43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/ajhp\/52.4.417","article-title":"ASHP guidelines on adverse drug reaction monitoring and reporting","volume":"52","author":"American Society of Health-System Pharmacists","year":"1995","journal-title":"Am J Health-Syst Pharm"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-225028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:18:07Z","timestamp":1756361887000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-225028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,17]]},"references-count":43,"alternative-id":["10.1136\/bcr-2018-225028"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-225028","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,17]]}}}